Internal Medicine, Hematology & Oncology · Chula Vista, CA
NPI
1437272010
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
855 3rd Ave Ste 3330
Chula Vista, CA, 91911
Phone (619) 745-1031
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.5M
133,124 services
Medicare patients, 2024
279
Average age 75
Drug cost, 2024
$4.5M
1,419 prescriptions
Company payments, 2025
$5,111
From 44 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ramesh K Moolani was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 17,800 times for 12 patients. In total Ramesh K Moolani billed 133,124 services in 92 codes, and Medicare paid $2.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-06-07.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 17,800 | 12 | $2.31 | $41K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,000 | 13 | $44.60 | $624K |
| J0897 Injection, denosumab, 1 mg | Office | 9,608 | 22 | $20.67 | $199K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,106 | 18 | $0.09 | $98.98 |
| 36415 Venipuncture Blood Collection | Office | 866 | 252 | $8.65 | $7,491 |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 744 | 15 | $111.10 | $83K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 540 | 11 | $0.59 | $320 |
| 99214 Office E&M - Established | Office | 321 | 112 | $100.72 | $32K |
| 96372 Injection Administration | Office | 288 | 44 | $12.15 | $3,501 |
| 96413 Chemotherapy Administration | Office | 254 | 35 | $115.83 | $29K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 206 | 14 | $4.95 | $1,020 |
| 96417 Chemotherapy Administration | Office | 153 | 20 | $57.60 | $8,813 |
| 96367 Intravenous Infusion, Hydration | Office | 143 | 20 | $25.35 | $3,626 |
| 85025 Blood Count | Office | 107 | 34 | $7.61 | $814 |
| 96415 Chemotherapy Administration | Office | 76 | 16 | $24.28 | $1,845 |
By year: 2022 $1.0M for 73,749 services; 2023 $1.7M for 92,274 services; 2024 $2.5M for 133,124 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 866 | 252 | $8.65 | $7,491 |
| 85025 Blood Count | 107 | 34 | $7.61 | $814 |
Medicare prescription drug claims, 2024
In 2024, the drug Ramesh K Moolani prescribed most often to Medicare patients was Letrozole, with 189 prescriptions and refills. In total Ramesh K Moolani wrote 1,419 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 189 | 407 | 49 | $3,398 |
| Omeprazole Generic | 90 | 140 | 31 | $639 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 81 | 81 | 26 | $1,973 |
| Ondansetron Odt Ondansetron | 70 | 71 | 40 | $1,611 |
| Anastrozole Generic | 46 | 111 | 12 | $960 |
| Naproxen Generic | 45 | 45 | 21 | $239 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 35 | 35 | Under 11 | $316 |
| Imbruvica Ibrutinib | 35 | 35 | Under 11 | $586K |
| Dexamethasone Generic | 34 | 39 | 20 | $726 |
| Lenalidomide Generic | 30 | 30 | Under 11 | $346K |
| Zolpidem Tartrate Generic | 28 | 28 | Under 11 | $124 |
| Nubeqa Darolutamide | 24 | 24 | Under 11 | $325K |
| Pregabalin Generic | 23 | 23 | Under 11 | $1,124 |
| Kisqali Ribociclib Succinate | 22 | 22 | Under 11 | $376K |
| Ibrance Palbociclib | 22 | 22 | Under 11 | $345K |
Brand drugs: 306 claims; generic drugs: 1,113 claims; opioid claims: 105.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ramesh K Moolani $5,111 ($5,111 in general payments such as food, travel and fees) from 44 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,257.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 25 | $1,257 |
| Merck Sharp & Dohme LLC MRK | 14 | $398 |
| Janssen Biotech, Inc. JNJ | 11 | $366 |
| E.R. Squibb & Sons, L.L.C. BMY | 16 | $258 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $227 |
| Pfizer Inc. PFE | 10 | $225 |
| Abbvie Inc. ABBV | 10 | $219 |
| Sobi, Inc SOBI.ST | 6 | $193 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 8 | $164 |
| Eisai Inc. 4523.T | 6 | $153 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.